-

MedinCell Secures €10.9 Million Non-Dilutive Financing

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL):

€10.9 million loan to increase the Company's financial visibility

Loan taken out with Banque Populaire du Sud and BNP Paribas in the form of PGE

Annual results for the FY ended March 31, 2020 will be published on June 4, 2020, after market close. As a reminder, a dedicated videoconference will be held at this occasion on Thursday, June 4:

  • 6.30 pm CEST – Presentation and Q&A in French
  • 7.30 pm CEST – Presentation and Q&A in English
  • Link to connect (only via internet): invest.medincell.com/conference

"We have maintained all operations related to strategic research and development programs since the beginning of the Coronavirus crisis, but other activities have been delayed," said Jaime Arango, Chief Financial Officer of MedinCell.

"Thanks to our partner banks who quickly mobilized to grant us this loan, we will be able to gradually return to normal activity level and advance as quickly as possible our Covid-19 program, which aims to develop a preventive treatment against the virus (prophylaxis)."

"The second half of the year should be rich for MedinCell, with potential milestones for several products based on our BEPO® technology currently in clinical studies. "

The loan is structured as a PGE (State Guaranteed Loan) with an initial maturity of 12 months at a 0,25% rate and an option for up to 5 years extension.

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

More News From MedinCell

Medincell Announces the Availability of Its 2025-26 Universal Registration Document Including the Annual Financial and CSR Reports

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): The 2025-26 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.26-0554 includes: the Annual Financial Report for the year ending on March 31, 2026 the management report the CSR report the report on corporate governance the proposed text of the resolutions to be submitted to the Shareholders' Meeting of September 30, 2026 The U...

Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth....

Medincell Continues to Strengthen and Renew Its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next...
Back to Newsroom